Antibodies

09 Jul 2009 DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAX
09 Jul 2009 Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products
08 Jul 2009 ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)
08 Jul 2009 Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
06 Jul 2009 Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Zevalin
06 Jul 2009 MorphoSys Secures Full-Term of Strategic Alliance
03 Jul 2009 Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
03 Jul 2009 ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
02 Jul 2009 Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
01 Jul 2009 Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
30 Jun 2009 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
29 Jun 2009 ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R
26 Jun 2009 Cimzia®, the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis
26 Jun 2009 SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
26 Jun 2009 European Regulator Gives Positive Opinion for the use of Avastin in Combination With docetaxel for the First-Line Treatment of Advanced Breast Cancer
24 Jun 2009 MorphoSys Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis
24 Jun 2009 Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in Philippines
23 Jun 2009 Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
18 Jun 2009 Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
18 Jun 2009 Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
18 Jun 2009 New biological therapy Ilaris® approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease
17 Jun 2009 CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
16 Jun 2009 MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
16 Jun 2009 FDA EXTENDS REVIEW OF ARZERRA™ (OFATUMUMAB)
16 Jun 2009 MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top